CureVac Past Earnings Performance

Past criteria checks 3/6

CureVac has been growing earnings at an average annual rate of 15.8%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 50.1% per year. CureVac's return on equity is 27.9%, and it has net margins of 34.5%.

Key information

15.82%

Earnings growth rate

106.57%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate50.08%
Return on equity27.94%
Net Margin34.50%
Last Earnings Update31 Mar 2025

Recent past performance updates

The Strong Earnings Posted By CureVac (NASDAQ:CVAC) Are A Good Indication Of The Strength Of The Business

May 27
The Strong Earnings Posted By CureVac (NASDAQ:CVAC) Are A Good Indication Of The Strength Of The Business

Recent updates

The Strong Earnings Posted By CureVac (NASDAQ:CVAC) Are A Good Indication Of The Strength Of The Business

May 27
The Strong Earnings Posted By CureVac (NASDAQ:CVAC) Are A Good Indication Of The Strength Of The Business
author-image

GSK Milestones And Tech Focus Will Shape Oncology Amid Risks

Strategic focus on innovation and R&D in oncology and infectious diseases positions CureVac for potential high-growth opportunities and revenue enhancement.

CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth

May 01
CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth

CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions

Mar 28

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

Jan 08

Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25%

Jan 04
Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25%

CureVac: Back To Square One

Oct 08

CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

Sep 16
CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

Aug 03
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

Jul 05
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas

Jul 04

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

Jun 01
Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26
What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01
Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

CureVac BV reports Q2 results

Aug 18

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

Jul 05

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

May 02
Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

Oct 28
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

CureVac: Wait For Concrete News Before Investing

Sep 01

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Revenue & Expenses Breakdown

How CureVac makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:CVAC Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2552418172163
31 Dec 2453516274153
30 Sep 24304-7784138
30 Jun 2466-27885116
31 Mar 2459-27392119
31 Dec 2354-26096116
30 Sep 2343-30295110
30 Jun 2338-30110395
31 Mar 2350-29110676
31 Dec 2267-24910763
30 Sep 2297-122100566
30 Jun 22115-219103602
31 Mar 22117-313105722
31 Dec 21103-412102816
30 Sep 2168-468102322
30 Jun 2144-36181308
31 Mar 2156-21964208
31 Dec 2049-12954114
30 Sep 2050-1075689
31 Mar 2017-1025643
31 Dec 1917-1005143
31 Dec 1813-712642

Quality Earnings: CVAC has a high level of non-cash earnings.

Growing Profit Margin: CVAC became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CVAC has become profitable over the past 5 years, growing earnings by 15.8% per year.

Accelerating Growth: CVAC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CVAC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).


Return on Equity

High ROE: CVAC's Return on Equity (27.9%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/29 06:21
End of Day Share Price 2025/05/29 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CureVac N.V. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Douglas BuchananCitizens JMP Securities, LLC
Martin AusterCredit Suisse